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Background: Haptoglobin (Hp) prevents hemoglobin (Hb) extravasation and attenuates
Hb induced tissue oxidation and vasoconstriction. Small animal models such as mouse,
rat and guinea pig appear to demonstrate proof-of-concept for Hb neutralization by
Hp in diverse pre-clinical conditions. However, these species differ significantly from
humans in the clearance of Hb:Hp and demonstrate long persistence of circulating Hb:Hp
complexes.
Objective: The focus of this study is to understand Hb:Hp clearance in a non-rodent
species. In contrast to rodents, dogs maintain high plasma Hp concentrations comparable
to humans and demonstrate more rapid clearance of Hb:Hp when compared to
rodent species, therefore dogs may represent a relevant species to evaluate Hb:Hp
pharmacokinetics and cellular clearance.
Results: In this study we show, that like human macrophages, dog peripheral blood
monocyte derived macrophages express a glucocorticoid inducible endocytic clearance
pathways with a high specificity for the Hb:Hp complex. Evaluating the Beagle dog as
a non-rodent model species we provide the first pharmacokinetic parameter estimates
of free Hb and Hb:Hp complexes. The data demonstrate a significantly reduced volume
of distribution (Vc) for Hb:Hp compared to free Hb, increased maximum plasma
concentrations and areas under plasma concentration time curves (Cmax and AUC).
Significantly reduced total body clearance (CL) and a longer terminal half-life (t1/2) of
approximately 12 h were also observed for the Hb:Hp complex. Distribution and clearance
were identical for dimeric and multimeric Hb:Hp complexes. We found no significant effect
of a high-dose glucocorticoid treatment protocol on Hb:Hp pharmacokinetic parameter
estimates.
Conclusion: Collectively, our study supports the dog as a non-rodent animal model to
study pharmacological and pharmacokinetic aspects of Hb clearance systems and apply
the model to studying Hp as a therapeutic in diseases of hemolysis.
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INTRODUCTION
Haptoglobin (Hp) therapy may be of benefit during hemolytic
states to bind and sequester cell free hemoglobin (Hb) within the
vascular compartment (Schaer and Buehler, 2013). Hp decreases
the interaction of Hb with critical organ systems and may atten-
uate free Hb triggered events such as vascular dysfunction and
renal injury (Baek et al., 2012). Currently, plasma derived Hp
is marketed in Japan with indications for trauma, burn and
massive blood transfusion (Schaer et al., 2013). However, several
off-label uses of Hp are reported in the literature as individual
case studies or small clinical trials in various situations of acute
hemolysis (Hashimoto et al., 1993; Yamamoto et al., 2000; Eda
et al., 2001). Recent interest within Europe and the US to develop
plasma derived Hp as a biologic therapeutic for uses in both
acute and chronic hemolytic disease states have been suggested
(Schaer et al., 2013). Therefore, understanding the pharmacologic
and pharmacokinetic relevance of animal species for predict-
ing human response is a critical aspect of the proof of concept
and pre- clinical safety evaluation for Hp therapeutics in early
development.
Hp is a α2-sialoglycoprotein and the primary Hb-binding pro-
tein in plasma. Hp exists in humans as a multi-phenotype protein
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designated as Hp 1-1, Hp 2-1, and Hp 2-2 (Connell et al., 1962).
Normal Hp concentrations in tissue and plasma are within a
range between 0.5 and 2mg/ml (Nosslin and Nyman, 1958; Levy
et al., 2010). The dimeric (1-1) and themultimeric forms (2-1 and
2-2) of Hp contain identical β globin chains involved in Hb dimer
binding (Andersen et al., 2012), but differ in their α globin chains,
which contain either one cysteine (α1) or two cysteines (α2) that
are involved in disulfide bond formation (Connell et al., 1962;
Smithies et al., 1962a,b). Therefore, the multi-phenotype desig-
nation is dependent on the proteins α1 and α2 content (Connell
et al., 1962). Conflicting reports either do or do not support spe-
cific protective properties of Hp phenotypes (Lipiski et al., 2013;
Asleh et al., 2014).
Clearance of Hb:Hp complexes has been suggested to occur
via tissue (spleen and liver) resident macrophages (Kristiansen
et al., 2001; Schaer et al., 2007). These cells typically express a high
surface concentration of CD163 and maximal heme oxygenase-1
(HO-1) enzymatic capacity (Zwadlo et al., 1987). CD163 is a
cell surface protein exclusive to monocytes/macrophages and is
the putative 9—domain receptor for binding and internalization
of Hb:Hp complexes (Kristiansen et al., 2001). Further detox-
ification of heme takes place via HO-1 to liberate free iron,
which is then bound to the ferritin complex until it is reuti-
lized. Monocyte/macrophage clearance may be saturated when
supra-physiological concentrations of Hb:Hp complex result
from therapeutic Hp administration during hemolysis and this
may lead to extended circulation of Hb:Hp within the vas-
cular space. With interest in development of Hp as a bio-
logic therapeutic it remains important to identify species with
a “human-like” functional monocyte/macrophage Hb:Hp clear-
ance system that could serve to model Hb:Hp clearance in
humans.
Our rationale for evaluating the dog as a model is based
on several aspects of Hb clearance systems observed in canines
that appear to approximate humans. For example, in contrast
to rodents, human and dog have high basal plasma concen-
trations of Hp (Boretti et al., 2009). We previously reported
that dogs are responsive to up-regulation of Hp following glu-
cocorticoid dosing and this leads to attenuation of the acute
effects of Hb exposure (Boretti et al., 2009). In these stud-
ies we observed, that glucocorticoid treated dogs exposed to
cell free Hb accumulated high intravascular concentrations of
Hb:Hp complexes that were cleared within 24 h. Based on these
observations we hypothesized that the clearance system for cell
free Hb in dogs may approximate that of humans. As a result
the dog may estimate the pharmacokinetic response to supra-
physiological Hb:Hp exposure and allow for evaluation of the
pharmacokinetics of Hb following in vivo binding to differing Hp
phenotypes.
The present study was designed to (1) characterize the Hb:Hp
clearance system of dog macrophages in vitro based on the well-
defined characteristics of the human system, (2) evaluate the
effects of glucocorticoid pre-treatment on the pharmacokinet-
ics of Hb and Hb:Hp complexes in the dog and (3) evaluate
the pharmacokinetics of Hb and Hb:Hp complexes following the
administration of two pre-clinical grade human Hps purified as
dimeric or multimeric phenotype composition.
MATERIALS AND METHODS
MATERIALS
Human and dog Hb was prepared using a standardized method
previously described (Palmer et al., 2009). Human plasma frac-
tionated Hp predominantly in the dimeric form (Hp 1-1)
was provided by BioProducts Laboratory (Elstree, UK). Human
plasma fractionated Hp predominantly in the multimeric forms
(Hp 2-1 and Hp 2-2) was provided by CSL Behring (Kankakee,
Illinois, USA). Concentrations of Hb and Hp solutions were pre-
pared as 10 and 6 g/dl, respectively. Reducing and non-reducing
gels were carried out according to existing protocols outlined by
Life Technologies™ Protocols.
PREPARATION OF DOG MACROPHAGES
Mononuclear cells were prepared from heparin anti-coagulated
beagle dog blood by Ficoll Paque centrifugation at 420 g for
25min. After washing twice in phosphate buffered saline (PBS)
the CD14+ monocytes were isolated from the mononuclear cell
fraction by magnetic cell separation using anti-CD14 magnetic
MACS beads (Miltenyi Biotec) according to the protocol provided
by the manufacturer. The isolated CD14+ monocytes were cul-
tured on glass coverslips in DMEMmedium containing 10% fetal
calf serum (FCS) in the presence of human M-CSF (100 ng/ml;
Peprotech) and dexamethasone (2.5 × 10−7 M; Sigma) as indi-
cated. According to our previous work, this concentration of dex-
amethasone induces maximum induction of CD163 and Hb:Hp
uptake in human macrophages (Schaer et al., 2002). To evaluate
the effect of dexamethasone treatment on Hb:Hp endocyto-
sis, macrophage were analyzed after 36 h in culture. We have
previously used this protocol to establish the Hb:Hp uptake stim-
ulation activity of glucocorticoid treatment in human PBMC
derived macrophages, and the same cell culture protocol pro-
vided evidence for robust CD163 expression in mouse peritoneal
macrophages (Schaer et al., 2001). To compare endocytosis capac-
ity for human and dog Hb:Hp we used a longer cell culture
protocol of 4 day (in the presence of M-CSF and dexamethasone).
After longer culture periods macrophages have a more mature
phenotype with maximum CD163 expression and high Hb:Hp
endocytic capacity (Schaer et al., 2006a; Kaempfer et al., 2011).
FLUORESCENT LABELING OF HUMAN AND DOG Hp
Dog Hp was from Lee Biosolutions (St. Louis, Missouri USA),
human Hp of the dimeric Hp 1-1 phenotype was from BPL
BioProducs Laboratory (Elstree, UK). Dog and human Hp were
diluted in PBS pH 8.0 to a concentration of 4mg/ml. 2mg Hp
were incubated with 100μg Alexa Fluor 488 succinimidyl ester
(NHS ester; Moelcular Probes) for 1 h in the dark at room tem-
perature. Subsequently, non-bound dye was removed by a PD-10
desalting column (GE Healthcare).
MEASUREMENT OF Hb:Hp ENDOCYTOSIS
Endocytosis of Hb:Hp complexes by dog macrophages was mea-
sured as reported previously by a modified fluorescent uptake
assay (Schaer et al., 2002, 2008). In our previous work we estab-
lished that labeling of Hb:Hp complexes with Alexa 488 does
not significantly affect endocytosis by CD163 (Schaer et al., 2002,
2006b). Dog macrophages were incubated Alexa 488 labeled dog
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or human Hp ± (non-labeled) Hb at a concentration of 10μg/ml
in serum free DMEMmedium for 30min at 5% CO2/37◦C. After
incubation the cells were washed with PBS and fixed with 4%
buffered formalin for 15min. Nuclei were stained with Hoechst
33342DNA stain. From each sample (cover slip) 20 randomwide-
field fluorescence images were acquired with a Zeiss Observer.Z1
microscope equipped with an Axiocam MRm camera and ZEN
2012 software (Carl Zeiss AG) at an optical magnification of
400x. All image acquisition parameters were set at fixed values
for the whole study and no further image processing was applied
before quantification. Digital image analysis was performed using
Cell Profiler image analysis software (Broad Institute; www.
cellprofiler.org) to (1) identify and count individual cells in the
Hoechst nuclear stain channel and (2) to quantify Alexa488 fluo-
rescence intensity per cell in the green channel image. Subtracted
background values were determined with macrophage samples
that have not been incubated with a fluorescent protein. Images
for illustration were acquired as Z-stack optical section images
from the identical samples using an Apotome.2 image acquisition
system at an optical magnification of 400x (Carl Zeiss AG). The
final images were composed using Fiji/ImageJ software (http://fiji.
sc/Fiji) with identical threshold values applied to all images.
DESIGN OF ANIMAL STUDIES
All studies were performed in accordance with the Swiss Academy
of Medical Sciences ethical principles and guidelines for exper-
iments on animals. The protocol for the study was reviewed
and approved by the Swiss Institutional Animal Care and Use
Committee as meeting the Swiss guidelines for laboratory animal
use. The present study was conducted to evaluate plasma concen-
tration vs. time data and pharmacokinetics following exogenous
Hb exposure of 4 g to seven separate groups of beagle dogs.
After implantation of a jugular cannula and recovery, conscious
Beagle dogs were randomized to 1 of 7 groups as follows: (1)
dog Hb, 4 g dose (n = 4); (2) human Hb, 4 g dose (n = 4); (3)
prednisone pre-treated (50mg/kg, twice daily, 3 days) (Martinez-
Subiela et al., 2004) + Dog Hb, 4 g dose (n = 6); (4) prednisone
pre-treated (50mg/kg, twice daily, 3 days) + human Hb, 4 g
dose (n = 6); (5) human Hb 4 g dose + dimeric human Hp,
4 g dose (n = 6); (6) human Hb 4 g dose + multimeric human
Hp, 4 g dose (n = 6) and (7) prednisone pre-treated (50mg/kg,
twice daily, 3 days) (Martinez-Subiela et al., 2004) + human
Hb, 4 g dose + multimeric Hp, 4 g dose (n = 6). Dosing regi-
men: Animals were first dosed over a 10min period with a 4 g
bolus of Hb (40ml, concentration 10 g/dl) followed immediately
by a 4 g dose of Hp dimeric or multimeric (67ml, concentra-
tion 6 g/dl) administered over a 10min period. Whole blood
(1ml) per sample was obtained from the jugular vein at base-
line and post Hb and Hp dosing: 5min., 0.25, 0.5, 0.75, 1.0, 1.5,
2.0, 2.5, 3, 3.5, 4.0, 5.0, 6.0, 8.0, 12, 16, 24, 32, 36, 48 and 60 h.
After the initial 24 h of blood collections, the jugular cannula was
removed and blood sampling until 60 h was performed using a
21 gauge needle and syringe. After the 60 h collection animals
were returned to their colony. Whole blood was collected in hep-
arinized 3ml syringes, centrifuged at 4000 rpm for 10min and
plasma was frozen at −80◦C until uv-visible spectrophotome-
try and size exclusion-high performance liquid chromatography
analysis. The speed of centrifugation did not lead to hemolysis. All
basal and final collection blood samples were free of extra-cellular
Hb based on visual and spectral analysis.
DETERMINATION OF PLASMA Hb CONCENTRATIONS
Plasma collected at baseline from each animal served as the blank
to correct for background interference and turbidity. Ferrous
heme (oxy/deoxy), ferric heme, and hemichrome were deter-
mined on photodiode array spectrophotometer (Model 8453
Hewlet Packard, Palo Alto, CA). Spectral data was evaluated using
a multi-component analysis based on the extinction coefficients
for each species and total hemewas calculated by adding these val-
ues (Winterbourn, 1985). The Plasma concentration time data are
represented as plasma heme micro-molar concentration bound
within Hb or Hb:Hp vs. time in hours. Free and Hp-bound Hb
were determined in plasma (50μL) by size exclusion chromatog-
raphy (SEC) run on a BioSep-SEC-S3000 (600 × 7.5mm) SEC
column (Phenomenex, Torrance, CA) attached to a Waters Delta
600 pump and Waters 2499 dual-wavelength detector, controlled
by a Waters 600 controller using Empower™ 2 software (Waters
Corp., Milford, MA). Peak areas for Hb and Hb:Hp obtained
at 405 nm were recorded. Calculations for percent free Hb were
determined as follows (Hb peak area/total Hb + Hb:Hp peak
areas) × 100 = percent free Hb. Heme concentrations from uv-
visible spectrometry x percent free Hb = free Hb concentration
(as μM heme). Similarly, Hb bound to Hp was calculated as fol-
lows (Hb:Hp peak area/total Hb + Hb:Hp peak areas) ×100 =
percent Hb bound to Hp (Hb:Hp). Heme concentrations from
uv-visible spectrometry × percent Hb:Hp = Hb concentration
(as μM heme) bound to Hp (Hb:Hp).
PHARMACOKINETIC PARAMETER ESTIMATE EVALUATION
A non-compartmental pharmacokinetic analysis was performed
on unbound Hb (group 1) and Hb bound to Hp (groups 2
and 3). PlasmaHb concentrations usingWinNonlin version 5.2.1,
Pharsight company (St. Louis, Missouri). Pharmacokinetic esti-
mates are expressed in tabular form as mean ± SEM. Maximal
plasma concentrations (Cmax) represent the greatest plasma con-
centration reached after dosing in each animal. Area under the
plasma concentration time curve (AUC0−inf) was estimated using
the linear trapezoidal rule to the last measurable concentration
(AUC0−Clast) where Clast is the last measurable plasma concen-
tration. Extrapolation to infinity (AUCClast−inf) was calculated by
dividing Clast by the negative value of the terminal slope (k) of
the log-linear plasma concentration-time curve. Thus, AUC0−∞
is equal to the sum of AUC0−Clast and AUCClast−inf. Additional
parameters were calculated as follows: the plasma clearance (CL)
was calculated as the dose divided by AUC0−inf, half-life (t1/2) was
calculated as ln(2) ∗ Vc/CL. Volumes of distribution of the central
compartment (Vc) are calculated as the product of dose (as heme
equivalents) divided by Cmax.
RESULTS
CHARACTERIZATION OF THE DOG MONOCYTE/MACROPHAGE Hb:Hp
COMPLEX CLEARANCE SYSTEM
To characterize the dog monocyte/macrophage system for clear-
ance of Hb:Hp complexes and to evaluate the potential validity
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of this animal model for studies with human Hp we have investi-
gated two essential functions that are characteristic for the human
monocyte/macrophageHb:Hp clearance system. These character-
istics are the glucocorticoid responsiveness of the human system
and the specificity for uptake of Hb:Hp complexes as opposed
to free Hp (Kristiansen et al., 2001; Schaer et al., 2002; Vallelian
et al., 2010). Figure 1A illustrates that after a short in vitro culture
period of 36 h only minimal fluorescent dog Hb:Hp is taken up
by dog macrophages. In contrast strong complex endocytosis can
be detected when the cells were pretreated with dexamethasone at
a concentration of 2.5 ×10−7 M. We have previously shown that
this treatment regimen induces Hb:Hp uptake capacity in human
PBMC derived macrophages (Schaer et al., 2002). Comparable
low endocytosis in untreated cells and strong glucocorticoid stim-
ulation of endocytosis was also observed in similar experiments
using human instead of dog Hp (not shown). Figure 1B shows
quantitative dog Hb:Hp complex uptake data that were obtained
with monocytes prepared from three different Beagles. Figure 2A
illustrates the minimal uptake of free fluorescent human and dog
Hp by macrophages that have been differentiated by M-CSF and
FIGURE 1 | Glucocorticoid induction of the dog macrophage Hb:Hp
clearance system. (A) Peripheral blood CD14+ monocytes from beagle
dogs were cultured for 36 h in the presence of M-CSF (control) or M-CSF +
dexamethasone (2.5 ×10−7 M) before they were incubated with
fluorescent dog Hb:Hp complexes for 30min. Images represent maximum
orthogonal projections of z-stack images acquired with an Apotome
fluorescence microscopy system. Blue: nuclei; orange: Hb:Hp complex.
Original optical magnification 400x. (B) Hb:Hp upake was quantified by
digital image analysis in control and dexamethasone treated macrophages
from three different beagle dogs, each condition is represented by 15
individual random images.
dexamethasone for 4 days to fully induce the clearance system. In
contrast, both dog and humanHp are strongly endocytosed in the
presence of equimolar concentrations of non-fluorescent human
Hb (identical results were obtained with dogHb, data not shown).
The Hb:Hp complexes accumulate in the perinuclear intracel-
lular compartment of the dog macrophages (Figure 2B). This
observation supports the specificity of the dog clearance system
for Hb:Hp complexes. Figure 2C provides quantitative endocy-
tosis data that have been obtained with macrophages prepared
from five different beagle dogs. Comparison of the background
corrected fluorescence signals may suggest that the dog Hb:Hp
complex is more efficiently taken up than the humanHb:Hp com-
plex. However, without more specific label free receptor-ligand
interaction studies it is impossible to discriminate whether the
relatively small difference reflects a true difference in Hb:Hp
endocytosis or whether it might be explained by slightly differ-
ent labeling or different stability of the two labeled complexes in
the lysosomal compartment of the dog macrophage. Apparently,
this in vitro observation does not reflect different in vivo clearance
of the two complexes.
The observation that both, dog and human Hb:Hp com-
plexes are taken up by dog macrophages via a specific clearance
system suggests that the dog might be an appropriate animal
model to study systemic clearance of human plasma derived Hp
therapeutics.
PHARMACOKINETICS OF DOG AND HUMAN Hb IN BEAGLE DOGS
To characterize potential differences in the pharmacokinetics of
dog and human Hb following acute exposures in Beagles, puri-
fied dog Hb [4 g dose (n = 4)] and human Hb [4 g dose (n = 4)]
was administered by bolus intravenous administration through
the jugular vein. Blood sampling was performed to cover the
range of plasma concentrations from Cmax until the absence of
Hb in plasma. Table 1 shows the mean ± SEM. pharmacoki-
netic parameter estimates for dog and human Hb. Figure 3A
shows the plot of mean ± SEM plasma concentration vs. time
data used to derive the pharmacokinetic parameters in Table 1.
Data are fit to a single exponential decay and do not consider
the differential kinetics of free Hb and Hb bound to the endoge-
nous dog Hp. Both dog and human Hb demonstrate comparable
pharmacokinetic parameters.
PHARMACOKINETICS OF DOG AND HUMAN Hb FOLLOWING
GLUCOCORTICOID UP-REGULATION OF ENDOGENOUS Hb CLEARANCE
SYSTEMS
To characterize the differences in the pharmacokinetics of free
Hb and Hb bound to Hp (Hb:Hp complex) we repeated the
above described study in glucocorticoid treated Beagles, which
have maximally induced endogenous Hp. Dogs were pre-treated
with prednisone (50mg, twice daily, 3 days) based on our pre-
vious studies (Boretti et al., 2009) and the studies of others
(Martinez-Subiela et al., 2004). On day 4 dogs were random-
ized to groups receiving dog Hb [4 g dose (n = 6)] or human Hb
[4 g dose (n = 6)] administered by bolus intravenous administra-
tion through the jugular vein. Blood sampling was performed to
cover the range of plasma concentrations from Cmax until the
absence of Hb:Hp in plasma. Table 2 shows the mean ± SEM
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FIGURE 2 | Specificity of the dog macrophage clearance system for
Hb:Hp complexes. (A) Peripheral blood CD14+ monocytes from beagle
dogs were cultured for 4 days in the presence of M-CSF + dexamethasone
(2.5 ×10−7 M) before they were incubated with fluorescent (Alexa488) dog
or human Hp with or without Hb for 30min. Images are single optical
sections acquired with an Apotome fluorescence microscopy system. Blue:
nuclei; Orange: Hb:Hp complex. Original optical magnification 400x. (B)
Fluorescence signals of a single optical apotome section as shown in (A)
overlaid on a DIC bright-field image, which indicates cell boarders and
intracellular localization of the endocytosed Hb:Hp complexes in the
perinuclear region of the macrophages. Blue: nuclei; Yellow: Hb:Hp
complex. (C) Dog and human Hp ± Hb uptake was quantified by digital
image analysis in macrophages from five different beagle dogs.
pharmacokinetic parameter estimates for dog and human Hb
unbound and bound to endogenous Hp. Figure 3B shows the
plot of mean ± SEM plasma concentration vs. time data for dog
Hb, while Figure 3C shows the plot of mean ± SEM plasma
concentration vs. time data for human Hb used to derive the
pharmacokinetic parameters shown in Table 2. Data are fit to
a single exponential decay and demonstrate that both dog and
humanHb are comparably bound to the glucocorticoid enhanced
endogenous dog Hp in vivo. Pharmacokinetic parameters of dog
and human Hb not bound to Hp demonstrate a low exposure
(Cmax and AUC), rapid CL and large Vc that expands beyond
the central compartment. This observation may be due to renal
distribution of unbound Hb, as hemoglobinuria was observed
following Hb exposure in the absence of Hp up-regulation or Hp
administration, consistent with previous studies (Boretti et al.,
2009; Lipiski et al., 2013). Both dog and human Hb bound to Hp
demonstrate comparable exposures (Cmax and AUC) and signif-
icantly reduced CL compared to unbound Hb. The Vc reflects the
volume of the central compartment in the Beagle and demon-
strates that the Hb:Hp complex remains sequestered within the
circulating blood volume. The t1/2 of the endogenous dog Hp
complex with dog or human Hb is highly comparable. The small
differences in Cmax and Vc observed at low plasma concen-
trations of unbound dog and human Hb may suggest minor
differences in Hb binding immediately after dosing. However,
the contribution to overall pharmacokinetic exposure was not
changed.
Collectively, these data suggest differences in distribution,
exposure and clearance of free Hb and the Hb:Hp com-
plex, and demonstrate that dog and human Hb follow similar
pharmacokinetics in Beagles when bound to Hp.
PHARMACOKINETICS OF HUMAN Hb FOLLOWING ADMINISTRATION
OF DIMERIC OR MULTIMERIC Hp
In a next study we characterized the pharmacokinetics of Hb fol-
lowing administration of dimeric (primarily 1-1) and multimeric
(2-1 and 2-2) human plasma derived Hp. These data should iden-
tify potential Hp phenotypic differences in exposure, distribution
and clearance after acute dosing. Furthermore, these data allowed
us to test for equivalence of dog and human Hb:Hp clearance
in Beagles. Dogs were randomized to groups administered 4 g
humanHb followed by dimeric humanHp, 4 g dose (n = 6) or 4 g
human Hb followed by multimeric human Hp, 4 g dose (n = 6).
All proteins were administered by bolus intravenous administra-
tion through the jugular vein. Blood sampling was performed to
cover the range of plasma concentrations from Cmax until the
absence of Hb:Hp in plasma. Table 3 shows the mean ± SEM
pharmacokinetic parameter estimates for free human Hb and
the different Hb:Hp complexes that formed in vivo. Figure 4A
shows the plot of mean ± SEM plasma concentration vs. time
data for Hb following dimeric Hp dosing, while Figure 4B shows
the plot for mean ± SEM plasma concentration vs. time data for
Hb following multimeric Hp dosing. Derived pharmacokinetic
parameters are shown in Table 3. Data are fit to a single expo-
nential decay and demonstrate that Hb is comparably bound to
dimeric and multimeric Hp in vivo. Pharmacokinetic parame-
ters of Hb bound to dimeric and multimeric Hp demonstrate
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Table 1 | Pharmacokinetic parameters of dog and human hemoglobin (Hb) (mean ± SEM) in Beagles.
Hemoglobin [heme] Cmax(µmol/L) AUC0–infinity(h*µmol/L) CL (L/h) Vc (L) t1/2(h)
Dog Hb (total) 358.3 ± 43.2 2075 ± 391 0.1353 ± 0.0265 0.7359 ± 0.106 3.936 ± 0.361
Human Hb (total) 377.2 ± 18.3 1929 ± 148 0.1319 ± 0.0100 0.667 ± 0.035 3.537 ± 0.148
FIGURE 3 | Pharmacokinetics of dog and human Hb ± glucocorticoid
up-regulation of Hb clearance systems. (A) Mean ± SEM plasma
concentration vs. time plotted for dog and human purified Hb administered
to beagle dogs (n = 4/treatment). Data are fitted to a single exponential
decay (red and green traces) and represent total heme bound to Hb +
Hb:Hp. Pharmacokinetic parameter estimates are shown in Table 1. (B)
Mean ± SEM plasma concentration vs. time plotted for prednisone
pre-treated Beagle dogs administered purified dog Hb (n = 6). Data
represent unbound and Hp bound concentrations in plasma. Data are fitted
to a single exponential decay and represent total heme bound to Hb +
Hb:Hp. Pharmacokinetic parameter estimates are shown in Table 2. (C)
Mean ± SEM plasma concentration vs. time plotted for prednisone
pretreated Beagle dogs administered purified human Hb (n = 6). Data
represent unbound and Hp bound concentrations in plasma. Data are fitted
to a single exponential decay (red and green traces) and represent total
heme bound to Hb + Hb:Hp. Pharmacokinetic parameter estimates are
shown in Table 2.
a comparable exposure (Cmax and AUC), significantly slower
CL and a contracted Vc compared to unbound Hb. The t1/2 of
the Hb:Hp dimeric and multimeric complex is highly compara-
ble in Beagles. These data support that dimeric and multimeric
Hb:Hp complexes demonstrate similar in vivo pharmacokinet-
ics. Overall, the pharmacokinetic parameters of both human Hp
complexes are highly comparable to the parameter estimates for
dog Hb:Hp complexes (Tables 2, 3). The plasma concentration
vs. time curves shown in Figures 4A,B demonstrate two distinct
phases. We speculate that this observation may be the result of
CD163 availability on the surface of monocytes and macrophages
over the duration of the experiment.
PHARMACOKINETICS OF Hb:Hp COMPLEXES IN GLUCOCORTICOID
TREATED DOGS
In vitro and in vivo stimulation of human peripheral blood
monocyte CD163 by glucocorticoids leads to increased uptake
of Hb:Hp complexes and we have demonstrated a comparable
response of dog monocytes. To test the contribution of the gluco-
corticoid inducible CD163 pool on in vivo pharmacokinetics we
evaluated the clearance of Hb:Hp complexes in animals that have
been pre-treated with 50mg prednisone, twice daily for 3 consec-
utive days, which corresponds to a dose of 7–10mg/kg/day. We
have previously shown in human patients with acute inflamma-
tory and autoimmune diseases that comparable immunosuppres-
sive glucocorticoid treatment protocols stimulate strong CD163
expression and Hb:Hp endocytosis capacity in peripheral blood
monocytes (Vallelian et al., 2010). Six dogs were dosed with
human Hb (4 g) and multimeric human Hp (4 g). Blood sam-
pling was performed to cover the range of plasma concentrations
from Cmax until the absence of Hb:Hp in plasma. Table 4 shows
the mean ± SEM pharmacokinetic parameter estimates for Hb
unbound and bound to Hp. Figure 4C shows the plot of mean ±
SEM plasma concentration vs. time data for Hb in the unbound
and Hp bound forms used to derive pharmacokinetic parameters
shown in Table 4. Data are fit to a single exponential decay and
demonstrate that Hb is entirely bound to Hp in vivo. This is the
result of both high endogenous Hp induced by prednisone and
exogenously administered human Hp. Pharmacokinetic values
for Hp boundHb show comparable values in all studies regardless
of the Hp species and demonstrate comparable exposures (Cmax
and AUC) and rates of CL for untreated and glucocorticoid-
treated dogs (Tables 2–4). Collectively, the data demonstrates that
glucocorticoid stimulation of CD163 in vivo does not contribute
more rapid clearance of Hb:Hp. The explanation for this obser-
vation is likely that the large pool of resident macrophages in the
liver and spleen constitutively express high levels of CD163, which
cannot be further stimulated by glucocorticoid administration.
Compared to this large pool of CD163+ resident spleen and
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Table 2 | Pharmacokinetic parameters of dog and human Hb (+) prednisone (mean ± SEM) in Beagles.
Hemoglobin [heme] Cmax (µmol/L) AUC0–infinity (h*µmol/L) CL (L/h) Vc (L) t1/2(h)
Dog Hb (unbound) 52.15±10.6 9.985±2.59 35.73±9.79 6.051±1.25 0.2006± 0.0787
Dog Hb (bound) 277.9±14.3 4798±405 0.05405±0.00463 0.912±0.0493 12.05± 1.04
Human Hb (unbound) 20.1±5.51 7.740±2.23 48.40±15.1 18.11±5.46 0.2657± 0.0185
Human Hb (bound) 353.7±18.0 5457±185.2 0.03538±0.00305 0.7562±0.0172 11.45± 0.527
(Unbound) and (bound) to Hp.
Table 3 | Pharmacokinetic parameters of Hb bound to dimeric and multimeric Hp (mean ± SEM) in Beagles.
Hemoglobin [heme] Cmax(µmol/L) AUC0–infinity (h*µmol/L) CL (L/h) Vc (L) t1/2(h)
DIMERIC Hp
Human Hb (unbound) 54.14 ± 4.95 78.63±16.9 3.711±0.862 5.022±0.463 1.034±0.139
Human Hb (bound) 353.7 ± 18.0 7234±656 0.03538±0.00306 0.7124±0.0368 14.15±0.956
MULTIMERIC Hp
Human Hb (unbound) 78.67 ± 2.82 64.89±17.8 5.156±1.30 3.193±0.109 0.5640±0.132
Human Hb (bound) 322.1 ± 23.6 6105±593 0.04297±0.00527 0.7939±0.0610 13.14±0.983
(Unbound) and (bound) to Hp.
liver macrophages, the highly glucocorticoid responsive pool of
peripheral blood monocytes is small and appears to provide a
minor contribution to systemic Hb:Hp clearance. The predom-
inant distribution of CD163+ monocytes and macrophages to
liver and spleen is demonstrated in both rodent and non-rodent
species (Granfeldt et al., 2013).
PLASMA PROFILES OF BOUND Hb:Hp COMPLEXES
Figure 5 (bottom panel) shows the SEC elution profiles of stan-
dard Hb and Hb:Hp complexes. Human and dog Hb demon-
strate an elution time of 20.7min. Dog Hb:Hp demonstrates
an elution time of 17.7min. Dog Hp is entirely in the dimeric
form, but likely differs from human dimeric Hp in terms of the
extent and distribution of glycosylation sites. This is observed in
the chromatographic elution profile of dimeric human Hb:Hp,
which elutes approximately 0.5min faster than Hb bound dog
Hp and indicates a slightly larger molecular size for the human
Hb:Hp complex. Multimeric human Hp shows a broad elution
profile between 12 and 16min and no dimeric Hp phenotype.
Figure 5 (bottom panel, inset) shows a gel electrophoresis of
dimeric and multimeric Hp preparations under non-reducing
and reducing conditions. The non-reducing gel shows the phe-
notype specific dimer-polymer distribution of the Hp products
used in our studies. The reducing gel shows the presence of pri-
marily α1 globin in dimeric Hp and α2 globin in multimeric
Hp preparations. Figure 5 (middle panel) shows representative
plasma samples from prednisone pre-treated animals following
Hb exposure±multimeric Hp. The elution time peak at 17.7min
represents prednisone induced dogHp bound toHb in both chro-
matograms (prednisone ± Hp). The elution time of multimeric
Hp:Hp is observed with primary peaks at 14.7 and 15.1min.
The smaller area of the multimeric Hb:Hp peak is consistent
with the large area of the dimeric dog Hp following prednisone
pre-treatment. Figure 5 (top panel) shows the distribution of
Hb bound to Hp after dimeric and multimeric human Hp dos-
ing. Samples show elution times of Hp bound Hb consistent
with purified standards. Samples represent the 1 h collection time
point.
DISCUSSION
PRIMARY FINDINGS
Here we present in vitro data, which suggests that the function
and fundamental regulatory pathways of the human and dog
macrophage clearance system for Hb:Hp complexes are compa-
rable. These in vitro observations strongly indicate that human
and dog demonstrate similar pharmacologic and pharmacoki-
netic responses to intravascular Hb:Hp exposure and that dog
may, therefore, be an appropriate model for the pre-clinical
characterization of Hp therapeutics.
We provide the first pharmacokinetic parameter estimates of
cell free Hb and its modulation by Hp therapeutics in a non-
rodent model. The data reflect a drastically reduced Vc of the
complex compared to free Hb, increased exposures (Cmax and
AUC) and significantly reduced CL with a t1/2 of approximately
12 h. These estimates were not significantly different for the
human and dog proteins, respectively. These data support the
concept whereby a major protective function of Hp is provided
by a limited expansion of the central compartment volume (Vc)
and as a result decreased tissue compartmentalization of free Hb.
Our in vivo pharmacokinetic studies suggest two additional
key findings.
First, the pharmacokinetics of Hp bound Hb following the
administration of dimeric and multimeric plasma derived human
Hp demonstrate comparable pharmacokinetic parameter esti-
mates. These data suggest that both Hb bound to dimeric and
multimeric Hp undergo similar handling by Beagle dog Hb
clearance pathways. Earlier in vitro studies have provided con-
flicting data on differential uptake and post-endocytic processing
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FIGURE 4 | Pharmacokinetics of human Hb following administration of
dimeric or multimeric Hp ± glucocorticoid up-regulation of Hb
clearance systems. (A) Mean ± SEM plasma concentration vs. time
plotted for human purified Hb + human purified dimeric Hp administered to
beagle dogs (n = 6). Data are fitted to a single exponential decay (red and
green traces) and represent total heme bound to Hb + Hb:Hp.
Pharmacokinetic parameter estimates are shown in Table 3. (B) Mean ±
SEM plasma concentration vs. time plotted for human purified Hb + human
purified multimeric Hp administered to beagle dogs (n = 6). Data are fitted
to a single exponential decay (red and green traces) and represent total
heme bound to Hb + Hb:Hp. Pharmacokinetic parameter estimates are
shown in Table 3. (C) Mean ± SEM plasma concentration vs. time plotted
for prednisone pre-treated Beagle dogs administered human purified Hb +
human purified multimeric Hp (n = 6). Gray circles represent Hb:Hp
complex and open circles represent unbound Hb. No unbound Hb was
detected, as result data is set to zero. Data are fitted to a single exponential
decay (red and green traces) and represent total heme bound to Hb +
Hb:Hp. Pharmacokinetic parameter estimates are shown in Table 4.
of dimeric and multimeric Hb:Hp complexes by CD163 (Asleh
et al., 2003, 2014; Lipiski et al., 2013). Our in vivo data sug-
gest that in a setting of acute therapeutic Hp administration
the phenotype composition of a product will most likely not
determine clearance and cumulative exposure. The endogenous
dog Hp is only expressed in a dimeric composition without other
Hps similar to the 2-1 or 2-2 phenotypes found in humans
(Mominoki et al., 1995). Moreover different glycosylation pat-
terns exist between dog and human Hp (Mominoki et al., 1995)
and this could potentially contribute to altered CD163 recep-
tor interactions. Given these known differences it is notable
that highly comparable exposure times and clearance rates are
observed in Beagle dogs with Hp proteins novel to the species.
This observation supports that the Hb:Hp clearance system is
conserved among non-rodent animal species and human.
Second, data from Figures 1, 2 clearly demonstrate that the
function and regulation of the dog macrophage Hb:Hp clearance
system is comparable to the human system. Both systems are spe-
cific to the Hb:Hp complex as opposed to free Hp (Kristiansen
et al., 2001). This specificity of the clearance system for the
complex helps to preserve high circulating Hp concentrations.
Additionally, the expression of the clearance system as well as
its down-stream effector pathways is strongly stimulated by glu-
cocorticoid treatment of peripheral blood monocytes (Schaer
et al., 2002, 2008). In human, the glucocorticoid stimulation of
Hb:Hp uptake triggers a complex differentiation pathway that
promotes monocyte differentiation into an anti-oxidative and
iron handling macrophage phenotype during increased extracel-
lular Hb exposure (Vallelian et al., 2010). Glucocorticoid stimula-
tion of Hb:Hp uptake by peripheral blood monocytes could also
enhance total body Hb:Hp clearance capacity, however this has
not been investigated so far. Our pharmacokinetic data suggest
that glucocorticoid stimulation of the peripheral blood mono-
cyte Hb:Hp clearance system does not significantly enhance sys-
temic Hb clearance, which appears to be predominantly mediated
by resident tissue macrophages in the liver and spleen. These
cells already express maximum levels of CD163 and high HO-1
enzymatic capacity under physiologic conditions (Zwadlo et al.,
1987).
STUDY LIMITATIONS
The shortcomings of this study are clearly that no data exists to
compare dog to human in terms of pharmacokinetics of Hb:Hp
complexes following exogenous administration during hemoly-
sis. In the future human studies evaluating the pharmacokinetics
of Hb:Hp will provide important information that will contribute
to the appropriate dosing and potential safety concerns associated
with long circulating Hb:Hp complexes if saturable pharmacoki-
netics are found to occur. Based on our data in dogs, Hb:Hp
complexes are cleared more rapidly than in rodent species.
NOVELTY
The novelty of the data presented identify the Beagle dog as rele-
vant species that may provide a better understanding of Hb:Hp
clearance in humans. These findings are applicable to recent
interests in developing plasma derived Hp as a biologic ther-
apeutic for uses in both acute and chronic hemolytic disease
states and provide data to support pharmacologic and pharma-
cokinetic similarity for predicting human safety. The data from
dogs follow single compartment pharmacokinetics with a Vc lim-
ited to the plasma compartment. The clearance from the plasma
compartment is slower than for Hb however much more rapid
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Table 4 | Pharmacokinetic parameters Hb bound to multimeric Hp (mean ± SEM) following prednisone treatment in Beagles.
Hemoglobin [heme] Cmax(µmol/L) AUC0–infinity(h*µmol/L) CL (L/h) Vc (L) t1/2(h)
Human Hb (unbound) — — — — —
Human Hb (bound) 397.0 ± 33.6 6534 ± 100 0.04185 ± 0.00587 0.6469 ± 0.0511 12.17 ± 0.157
(Unbound) and (bound) to Hp,—no free (unbound) Hb detected.
FIGURE 5 | Plasma profiles of bound Hb:Hp complexes. (Bottom panel)
SEC elution profiles of standard human Hb (solid red line), dog Hb (dashed
red line) and Hb:Hp complexes. Bottom panel inset shows gel
electrophoresis of dimeric and multimeric Hp preparations under
non-reducing and reducing conditions. (Middle panel) shows representative
plasma samples from prednisone pre-treated animals following Hb
exposure (±) multimeric Hp. (Top panel) shows the distribution of Hb
bound to Hp after dimeric and multimeric human Hp dosing.
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than in rodent species (Lipiski et al., 2013). We speculate that
more rapid pharmacokinetic clearance in vivo and the evidence
of cellular clearance in vitro suggest that the dog may be translat-
able to human. The identification of a non-rodent animal model
may also prevent the need for genetic modifications to human-
ize the clearance pathway of animal species to enhance human
predictability.
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